Kymera Therapeutics KYMR Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's total operating expenses?
- Kymera Therapeutics (KYMR) reported total operating expenses of $118.52M in Q1 2026.
- How has Kymera Therapeutics's total operating expenses changed year-over-year?
- Kymera Therapeutics's total operating expenses increased by 22.8% year-over-year, from $96.53M to $118.52M.
- What is the long-term trend for Kymera Therapeutics's total operating expenses?
- Over 4 years (2021 to 2025), Kymera Therapeutics's total operating expenses has grown at a 22.4% compound annual growth rate (CAGR), from $173.36M to $388.61M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.